Back to top

biotechnology: Archive

Ekta Bagri

BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?

Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.

AZNNegative Net Change JNJNegative Net Change BDTXPositive Net Change

Zacks Equity Research

RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress

Roche posts strong new data for Vabysmo in eye disease, with extended dosing and vision gains driving growth.

REGNPositive Net Change RHHBYPositive Net Change BAYRYNegative Net Change

Zacks Equity Research

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results

Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.

CRMDNegative Net Change KNSAPositive Net Change IMVTPositive Net Change PHARPositive Net Change

Zacks Equity Research

Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?

Black Diamond focuses on silevertinib for NSCLC and GBM, with key trial readouts due in late 2025 and FDA feedback expected in 2026.

AZNNegative Net Change JNJNegative Net Change BDTXPositive Net Change

Zacks Equity Research

Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results

CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.

BMYPositive Net Change CYTKPositive Net Change CRMDNegative Net Change KNSAPositive Net Change

Zacks Equity Research

Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol

EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol.

CRMDNegative Net Change EDITPositive Net Change KNSAPositive Net Change PHARPositive Net Change

Zacks Equity Research

NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy

Novartis strikes a $200M licensing deal with Arrowhead for ARO-SNCA, aiming to advance treatments for Parkinson???s Disease.

NVSPositive Net Change RHHBYPositive Net Change ARWRPositive Net Change

Ahan Chakraborty

Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?

CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.

PFEPositive Net Change AMPHPositive Net Change CRMDNegative Net Change

Ekta Bagri

Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?

Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.

RHHBYPositive Net Change BMYPositive Net Change MRKPositive Net Change

Urmimala Biswas

Investing in the Age of Longevity: Silver Economy Stocks in Focus

AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.

ABTPositive Net Change AMGNPositive Net Change MDTPositive Net Change SYKNegative Net Change DXCMNegative Net Change ABBVNegative Net Change

Ahan Chakraborty

NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?

Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.

NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change

Zacks Equity Research

ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win

Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.

ALNYNegative Net Change RHHBYPositive Net Change CRMDNegative Net Change KNSAPositive Net Change